US Patent

US11873296 — Solid forms of a dual RAF/MEK inhibitor

Method of Use · Assigned to Verastem Inc · Expires 2042-12-29 · 17y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent describes solid forms of a dual RAF/MEK inhibitor and methods for preparing and using them to treat cancer.

USPTO Abstract

Solid forms of a dual RAF/MEK inhibitor, pharmaceutical compositions thereof, oral dosage forms thereof, and methods of treating cancer are described herein. Also provided herein are processes for preparing solid forms of a dual RAF/MEK inhibitor and pharmaceutical compositions and oral dosage forms thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4196`	—

Patent Metadata

Patent number: US11873296
Jurisdiction: US
Classification: Method of Use
Expires: 2042-12-29
Drug substance claim: No
Drug product claim: Yes
Assignee: Verastem Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.